Management of atrial fibrillation in COVID-19 pandemic

Yu Feng Hu; Wen Han Cheng; Yuan Hung; Wen Yu Lin; Tze Fan Chao; Jo Nan Liao; Yenn Jiang Lin; Wei Shiang Lin; Yi Jen Chen; Shih Ann Chen

doi:10.1253/circj.CJ-20-0566

Management of atrial fibrillation in COVID-19 pandemic

Yu Feng Hu, Wen Han Cheng, Yuan Hung, Wen Yu Lin, Tze Fan Chao, Jo Nan Liao, Yenn Jiang Lin, Wei Shiang Lin, Yi Jen Chen, Shih Ann Chen

Taipei Municipal Wanfang Hospital

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

Original language	English
Pages (from-to)	1679-1685
Number of pages	7
Journal	Circulation Journal
Volume	84
Issue number	10
DOIs	https://doi.org/10.1253/circj.CJ-20-0566
Publication status	Published - Sept 25 2020

Keywords

Ablation
Antiarrhythmic drugs
Atrial fibrillation
Oral anticoagulation

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-20-0566

Cite this

@article{1ee209d753b34c4082fa4423fd3826a7,

title = "Management of atrial fibrillation in COVID-19 pandemic",

abstract = "The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.",

keywords = "Ablation, Antiarrhythmic drugs, Atrial fibrillation, Oral anticoagulation",

author = "Hu, {Yu Feng} and Cheng, {Wen Han} and Yuan Hung and Lin, {Wen Yu} and Chao, {Tze Fan} and Liao, {Jo Nan} and Lin, {Yenn Jiang} and Lin, {Wei Shiang} and Chen, {Yi Jen} and Chen, {Shih Ann}",

year = "2020",

month = sep,

day = "25",

doi = "10.1253/circj.CJ-20-0566",

language = "English",

volume = "84",

pages = "1679--1685",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "10",

}

TY - JOUR

T1 - Management of atrial fibrillation in COVID-19 pandemic

AU - Hu, Yu Feng

AU - Cheng, Wen Han

AU - Hung, Yuan

AU - Lin, Wen Yu

AU - Chao, Tze Fan

AU - Liao, Jo Nan

AU - Lin, Yenn Jiang

AU - Lin, Wei Shiang

AU - Chen, Yi Jen

AU - Chen, Shih Ann

PY - 2020/9/25

Y1 - 2020/9/25

N2 - The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

AB - The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.

KW - Ablation

KW - Antiarrhythmic drugs

KW - Atrial fibrillation

KW - Oral anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=85091808965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091808965&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-20-0566

DO - 10.1253/circj.CJ-20-0566

M3 - Review article

C2 - 32908073

AN - SCOPUS:85091808965

SN - 1346-9843

VL - 84

SP - 1679

EP - 1685

JO - Circulation Journal

JF - Circulation Journal

IS - 10

ER -

Management of atrial fibrillation in COVID-19 pandemic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this